Tentative Outline

Special Issue for Current Diabetes Reviews

Diabetes and Metabolic Syndrome Risk in Rheumatic Diseases

Guest Editor: Mary Chester M. Wasko, MD, MSc, Co-Editor: Tarun S. Sharma, MD

Aims & Scope:
The tremendous burden of diabetes mellitus (DM) in the general population has sparked a keen interest in studying the risk of DM and effective glucose control in rheumatic diseases as well. As cardiovascular morbidity and mortality are increased in these diseases, DM has been studied closely as a risk factor for accelerated atherosclerosis in rheumatic conditions. Although the incidence and prevalence of DM is not conclusively proven to be higher in rheumatic diseases compared to the normal population, insulin resistance is increased in rheumatic diseases, presumably owing to the high levels of inflammation and circulating cytokines, sedentary lifestyle, abnormal body composition, and the influence of chronic corticosteroids used to treat the underlying inflammatory diseases. Therefore, medications that control rheumatic disease activity and optimize glucose metabolism are an area of interest. Several studies have shown that some anti-rheumatic medications have a favorable effect on glucose metabolism in rheumatoid arthritis (RA). New work also suggests that short term low dose corticosteroids paradoxically may improve glycemic control in RA. Improving the glycemic profile in these chronically ill patients at high risk for cardiovascular disease is of the utmost importance. As further work in these areas is being pursued, reviewing the highlights of these exciting developments is of interest to providers in all fields of medicine.

Keywords: Diabetes, Rheumatic diseases, Cardiovascular disease, anti-rheumatic medications

Subtopics:
The subtopics to be covered within this issue are listed below:

1) Rheumatoid Arthritis, SLE and Risk of Diabetes: Androniki Bili, MD, MPH - Rheumatology, Geisinger Health System, Danville, PA. Email: a1bili@geisinger.edu

2) Psoriatic Arthritis and Risk of Diabetes: Mike Ward, MD – Chief, Clinical Trials and Outcome Branch, NIAMS. Email: michael.ward@nih.gov

3) Gout and Risk of Diabetes and CVD: Eswar Krishnan, MD - Rheumatology, Stanford University, Palo Alto, CA. Email: eswar.krishnan@stanford.edu

4) Anti-Rheumatic Medications (especially Hydroxychloroquine, Tumor Necrosis Factor-Inhibitors, and short term corticosteroids) and Glucose Metabolism: Mary Chester Wasko, MD, MSc and Tarun Sharma, MD, Allegheny Health Network, Pittsburgh, PA. Email: mCWasko@wpahs.org and tsharma@wpahs.org

5) Body Composition and Glucose Metabolism in Rheumatoid Arthritis: Jon Giles, MD, MPH - Rheumatology, Columbia University, NY, NY. Email: jtg2122@columbia.edu

Schedule:
- Manuscript submission deadline: 07/01/2016
- Peer Review Due: 08/01/2016
- Revision Due: 09/01/16
- Announcement of acceptance by the Guest Editors: 09/15/2016
- Final manuscripts due: 09/30/2016

Contacts:
Name: Mary Chester M. Wasko, MD, MSc
Guest Editor
Affiliation: Division Director, Rheumatology
Allegheny Health Network
Email: mcwasko@wpahs.org

Documents: 63
Citations: 3864
h-index: 21